No Data
Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
Iridex CEO Patrick Mercer Joins Board of Directors
Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And Wll Be Effective For Services Performed After Nov. 17
Express News | IRIDEX Corp: Encouraged That Transscleral Cyclophotocoagulation Remains Unaffected by Recent Glaucoma Lcd
Express News | IRIDEX Corp: IRIDEX's Cyclo G6 Product Family Is Unaffected by New Reimbursement Limitations